Generics attack validity of Neurim insomnia drug patent

Dentons 2019-04-05 8:28 pm By Miklos Bolza | Sydney

Please login to bookmark

Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals’ patent for its insomnia drug Circadin is invalid and should be revoked.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au